Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.
Drug makers and regulators take aim at Omicron.
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.